Testing the drug mirdametinib for children and young adults with low-grade glioma
Official title: SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests a drug called mirdametinib in young people with a brain tumor called low-grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary.
Read our full plain-language summary
What the trial team says
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Key facts
- Registry number
- NCT04923126
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
Where it is running
This trial lists 1 site.
-
Tennessee
- St. Jude Children's Research Hospital (Memphis)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.